NextBioMedical Co., Ltd. (389650) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for NextBioMedical Co., Ltd. (389650:KRX), powered by AI.

Current Price
₩44,900
P/E Ratio
-1194.7
Market Cap
371.7B
Sector
Healthcare
What is the NextBioMedical Co., Ltd. stock price forecast?

NextBioMedical Co., Ltd. is currently trading at ₩44,900. View real-time AI analysis on Alpha Lenz.

What is NextBioMedical Co., Ltd. insider trading activity?

View the latest insider trading data for NextBioMedical Co., Ltd. on Alpha Lenz.

What is NextBioMedical Co., Ltd.'s P/E ratio?

NextBioMedical Co., Ltd.'s P/E ratio is -1194.7.

NextBioMedical Co., Ltd.

KRX · 389650
₩44,900+2,900(+6.90%)Market closedKRX regular session 09:00–15:30 KST
Ask about NextBioMedical Co., Ltd.'s future dividend policy...
Alpha Chat Insight

NextBioMedical Co., Ltd. trades at a P/E of -1194.7 (undervalued) with modest ROE of -0.7%. 3Y revenue CAGR of 80.6% highlights clear growth momentum.

Ask for details

Company Overview

NextBioMedical Co., Ltd. is a distinguished entity in the healthcare and medical device industry. Specializing in the development and production of cutting-edge biomedical technologies, its primary purpose is to enhance patient care and improve clinical outcomes. The company's product portfolio includes advanced medical devices for various therapeutic applications, focusing on minimally invasive solutions that cater to cardiovascular, orthopedic, and surgical needs. NextBioMedical Co., Ltd. operates at the intersection of healthcare innovation and technological advancement, continually pushing the envelope in terms of efficacy and safety in medical treatments. The firm is integral to the broader medical device market, driven by an increasing demand for innovative healthcare solutions. Headquartered in South Korea, NextBioMedical is influential in both local and international markets, reflecting its commitment to quality and global health improvement. As part of the industrial biosciences ecosystem, it plays a critical role in advancing medical technology, contributing to life-saving innovations and the future of healthcare.

CEO이돈행
SectorHealthcare
IndustryBiotechnology
0

Company Statistics

FY 2025

Profile

₩371,650,141,400Market Cap
₩16,476,802,680Revenue
8.28MShares Out
0Employees

Margins

69.97%Gross
3.96%EBITDA
-4.37%Operating
-1.89%Pre-Tax
-1.89%Net

Valuation

-1194.70P/E
7.73P/B
22.56EV/Sales
570.36EV/EBITDA
-195.45P/FCF

Growth (CAGR)

80.65%Rev 3Yr
48.77%Rev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-0.53%ROA
-0.67%ROE
0.10%ROIC

Financial Health

₩6,789,096,840Cash & Cash Equivalents
₩4,369,094,060Net Debt
23.19%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

NextBioMedical Co., Ltd. (ticker: 389650) is a company listed on KRX in the Healthcare sector (Biotechnology). Market cap is $371.7B.

The current price is ₩44,900 with a P/E ratio of -1,194.7x and P/B of 7.73x.

ROE is -0.67% and operating margin is -4.37%. Annual revenue is $16.5B.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
NextBioMedical Co., Ltd. (389650) Stock Forecast 2026 ₩44,900 — Price, Financials & Analyst Targets | Alpha Lenz